These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks identifies Zoetis and Novartis as potential earnings-beat candidates based on positive Earnings ESPs and #3 (Hold) ranks. Zoetis has a +2.16% ESP, with a $1.54 most accurate EPS estimate versus $1.51 consensus, ahead of its November 5, 2026 report; Novartis has a +3.77% ESP, with a $2.31 estimate versus $2.23 consensus, ahead of its February 3, 2027 report. The article presents these as possibilities, not confirmed beats.

Analysis

The only actionable near-term signal is Zoetis (ZTS): its positive ESP is based on a modest gap between the latest estimate and consensus, with earnings scheduled for November 5. That may indicate improving estimate momentum, but it is not evidence of better underlying demand or a durable earnings revision cycle. A reported beat can still be a negative stock event if investors have already priced in stronger results, or if guidance, product mix, or forward commentary disappoints. The article’s historical hit-rate and return claims are promotional backtests; without methodology, transaction costs, and performance by regime, they should not be treated as a tradeable edge.

Novartis (NVS) has a larger stated ESP, but its February 3, 2027 report is 98 days away. That estimate spread is exposed to substantial intervening revisions and is not a near-term catalyst. The two names also have distinct business drivers; this article provides no basis for a relative-value trade or for inferring shared healthcare-sector strength. No company fundamentals, valuation, options pricing, or market-implied earnings moves are supplied, so the signal supports monitoring rather than an outright directional position. Near term, revisions and positioning can dominate; over 1–3 months, guidance and subsequent estimate changes matter more than a single beat. The structural case is unaddressed.

Key Decisions for Investors

• Put ZTS on the November 5 event watchlist, not an automatic pre-earnings long. Verify the latest estimate revisions, business-line performance, management guidance, and the options-implied move before sizing any position.
• Treat NVS’s +3.77% ESP as a low-conviction watch item until closer to its February report; reassess after intervening estimate revisions rather than carrying an earnings thesis from today.
• If considering a defined-risk ZTS call spread, only evaluate it after comparing its cost and breakeven with the options-implied move and historical post-earnings moves; those data are absent here, so this is not yet a recommendation.
• Falsify the positive ZTS setup if the estimate advantage disappears or turns negative before the release, or if results/guidance disappoint and the stock underperforms despite a headline beat. A beat without stronger forward estimates is not confirmation.